JP2017052783A5 - - Google Patents

Download PDF

Info

Publication number
JP2017052783A5
JP2017052783A5 JP2016219822A JP2016219822A JP2017052783A5 JP 2017052783 A5 JP2017052783 A5 JP 2017052783A5 JP 2016219822 A JP2016219822 A JP 2016219822A JP 2016219822 A JP2016219822 A JP 2016219822A JP 2017052783 A5 JP2017052783 A5 JP 2017052783A5
Authority
JP
Japan
Prior art keywords
polypeptide
serum
level
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016219822A
Other languages
English (en)
Japanese (ja)
Other versions
JP6247734B2 (ja
JP2017052783A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017052783A publication Critical patent/JP2017052783A/ja
Publication of JP2017052783A5 publication Critical patent/JP2017052783A5/ja
Application granted granted Critical
Publication of JP6247734B2 publication Critical patent/JP6247734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016219822A 2010-10-01 2016-11-10 アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 Active JP6247734B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201070423 2010-10-01
DKPA201070423 2010-10-01
US39079110P 2010-10-07 2010-10-07
US61/390,791 2010-10-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013530569A Division JP6149226B2 (ja) 2010-10-01 2011-09-30 アロディニア、痛覚過敏、自発痛及び幻肢痛の処置

Publications (3)

Publication Number Publication Date
JP2017052783A JP2017052783A (ja) 2017-03-16
JP2017052783A5 true JP2017052783A5 (https=) 2017-11-09
JP6247734B2 JP6247734B2 (ja) 2017-12-13

Family

ID=59278857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013530569A Active JP6149226B2 (ja) 2010-10-01 2011-09-30 アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
JP2016219822A Active JP6247734B2 (ja) 2010-10-01 2016-11-10 アロディニア、痛覚過敏、自発痛及び幻肢痛の処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013530569A Active JP6149226B2 (ja) 2010-10-01 2011-09-30 アロディニア、痛覚過敏、自発痛及び幻肢痛の処置

Country Status (9)

Country Link
US (3) US8404642B2 (https=)
EP (1) EP2621512B1 (https=)
JP (2) JP6149226B2 (https=)
KR (1) KR101886029B1 (https=)
CN (2) CN108079279B (https=)
AU (1) AU2011307488B2 (https=)
CA (1) CA2813013C (https=)
ES (1) ES2584068T3 (https=)
WO (1) WO2012041328A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2195013T3 (da) 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
JP6145667B2 (ja) 2011-09-05 2017-06-14 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛、及び幻痛の治療
CN103685771A (zh) * 2013-12-13 2014-03-26 苏州士丹尼信息技术有限公司 一种集成的信息交流系统
CN107184956B (zh) * 2016-03-14 2020-09-08 上海风劲生物医药科技有限公司 Metrnl蛋白或基因在防治脓毒血症方面的应用
CN113785201B (zh) * 2019-02-08 2024-09-27 百进生物科技公司 用于检测镍纹蛋白-β活性的方法
CA3217602A1 (en) 2021-05-06 2022-11-10 Kenneth Petersen Prevention and treatment of chemotherapy-induced neuropathic pain
CA3239550A1 (en) 2021-12-10 2023-06-15 Kenneth Petersen Treatment of nociceptive pain

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
DK0639225T3 (da) 1992-04-30 2003-02-17 Innogenetics Nv Nye polypeptider og peptider, nucleinsyrer, der koder for dem, og deres anvendelse i området tumorterapi, inflammation eller immunologi
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
NZ269041A (en) 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
AU7452300A (en) 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
EP1233779A2 (en) 1999-11-30 2002-08-28 Innogenetics N.V. New uses of suppressive macrophage activation factors
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055440A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2403901A1 (en) 2000-05-02 2001-11-08 Human Genome Sciences, Inc. 29 human secreted proteins
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
CN1525866B (zh) 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
WO2003066877A2 (en) 2001-12-21 2003-08-14 Diadexus, Inc. Compositions and methods relating to hepatic specific genes and proteins
WO2004035732A2 (en) 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004079014A2 (en) 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
AU2005229434B2 (en) * 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
US20070161696A1 (en) * 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP1883446B8 (en) 2005-05-17 2017-11-15 Gloria Therapeutics Sarl An implantable therapy system for treating a living being with an active factor
EP1940471A1 (en) 2005-10-28 2008-07-09 NsGene A/S IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF
US20100323000A1 (en) 2006-02-24 2010-12-23 Neopharm, Inc. Method and process for preparing cardiolipin
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US7960345B2 (en) * 2007-05-02 2011-06-14 Snu R&Db Foundation Angiogenesis inhibitor comprising meteorin as an active ingredient
KR100823156B1 (ko) * 2007-05-02 2008-04-22 재단법인서울대학교산학협력재단 메테오린을 유효성분으로 포함하는 혈관신생 억제제
WO2009069764A1 (ja) * 2007-11-30 2009-06-04 National University Corporation Chiba University オピオイド鎮痛剤
DK2195013T3 (da) * 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
JP5937353B2 (ja) * 2008-08-19 2016-06-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap 冷感−メントール受容体拮抗剤
CN102202677A (zh) * 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
TW201031650A (en) * 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain

Similar Documents

Publication Publication Date Title
JP2017052783A5 (https=)
JP2015214545A5 (https=)
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
JP2016509011A5 (https=)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
JP2017532343A5 (https=)
JP2011250797A5 (https=)
JP2016529229A5 (https=)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
RU2016151179A (ru) Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента
WO2016042561A3 (en) Downregulating mir-132 for the treatment of lipid related disorders
RU2017145271A (ru) Терапевтическое средство для фиброза
BR112021013096A2 (pt) Tratamento de doença de sjögren com proteínas de fusão de nuclease
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
MY205028A (en) Protein for treatment of inflammatory diseases
RU2016107873A (ru) Пептиды
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
JP2017517561A5 (https=)
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
JP2013504519A5 (https=)